LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)
单位:[1]Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University首都医科大学附属安贞医院[2]Internal Medicine Department, China-Japan Friendship Hospital,[3]Department of Cardiology, Peking University People’s Hospital, Beijing,[4]Department of Cardiology, the People’s Hospital of Liaoning Province, Shenyang[5]Department of Cardiology, the First Hospital of Jilin University, Changchun, China
Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the efficacy of persistent treatment in a real-world setting may vary from regions. Routine lipid-lowering therapy in the region with a high prevalence of cardiovascular disease may lead to more failures of goal attainment. We therefore performed a study to observe different lipid-lowering strategies in northeast (NE) China with respect to low-density lipoprotein-cholesterol (LDL-C) reduction and goal attainments. A cross-sectional study (DYSIS-China) was conducted in 2012, involving 25,317 patients from 122 centers across China who were diagnosed with hyperlipidemia and treated with lipid-lowering therapy for at least 3 months. Of these patients, 4559 (18.0%) were assigned to the NE group according to their residential zones. Patients in the NE group tended to be younger, female, overweight, and had more comorbidities and higher blood lipid levels than those in the non-NE group (P<. 001). The goal attainment for LDL-C in NE was lower than non-NE (45.3% vs 65.1%, P<. 001), and especially lower in high (NE vs non-NE, 38.5%vs 58.6%) and very high (NE vs non-NE, 22.6% vs 43.7%) risk patients. The proportion of high intensity statin was lower in NE than non-NE, and the proportion of combination therapy was similar (similar to 2%). However, the goal attainment did not increase after administering higher dosages of statins in 2 groups. Logistic regression analysis identified diabetes mellitus (DM), coronary heart disease (CHD), cerebrovascular disease (CBD), being female, body mass index (BMI) >24kg/m(2), drinking alcohol, smoking, and being residence in NE China as independent predictors of LDL-C attainment. Despite having received persistent lipid-lowering treatments, the current situation of dyslipidemia patients in NE China is unsatisfactory. The main treatment gap might be related to the choice of statin and effective combination therapy and the control of comorbidities and obesity, especially for high-risk patients.
第一作者单位:[1]Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University
共同第一作者:
通讯作者:
通讯机构:[5]Department of Cardiology, the First Hospital of Jilin University, Changchun, China[*1]Cardiology Department, the First Hospital of Jilin University, Changchun 130021, China
推荐引用方式(GB/T 7714):
Zheng Wen,Zhang Yu-Jiao,Bu Xiang-Ting,et al.LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)[J].MEDICINE.2017,96(46):doi:10.1097/MD.0000000000008555.
APA:
Zheng, Wen,Zhang, Yu-Jiao,Bu, Xiang-Ting,Guo, Xin-Zhu,Hu, Da-Yi...&Sun, Jian.(2017).LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China Subgroup analysis of the dyslipidemia international study of China (DYSIS-China).MEDICINE,96,(46)
MLA:
Zheng, Wen,et al."LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)".MEDICINE 96..46(2017)